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Abstract
Background: Glucosamine (GlcN) is a well-recognized candidate for treatment of osteoarthritis. However, it is currently
used in derivative forms, such as glucosamine-hydrochloride (GlcN-HCl) or glucosamine sulfate (GlcN-S). However, the
molecular mode of action remains unclear. In this study, we compared the effects of Glucose (Glc), Glucuronic acid (GlcA),
Glucosamine hydrochloride (GlcN-HCl) and Glucosamine sulfate (GlcN-S) on cartilage degradation.
Methods: Porcine cartilage explants were co-cultured with recombinant human IL-1b and each tested substance for
3 days. HA, s-GAG and MMP-2 releases to media were measured using ELISA, dye-binding assay and gelatin
zymography, respectively. Similar studies were performed in a human articular chondrocytes (HAC) monolayer
culture, where cells were co-treated with IL-1b and each reagent for 24 hours. Subsequently, cells were harvested
and gene expression measured using RT-PCR. All experiments were carried out in triplicate. Student’s t-tests were
used for statistical analysis.
Results: In cartilage explants treated with IL-1b, GlcN-S had the highest chondroprotective activity of all four
chemicals as shown by the inhibition of HA, s-GAG and MMP-2 released from cartilage. The anabolic (aggrecan
core protein; AGG, SOX9) and catabolic (MMP-3, -13) genes in HACs treated with IL-1b and with/without chemicals
were studied using RT-PCR. It was found that, GlcN-HCl and GlcN-S could reduce the expression of both MMP-3
and -13 genes. The IL-1b induced-MMP-13 gene expression was decreased maximally by GlcN-S, while the
reduction of induced-MMP-3 gene expression was greatest with GlcN-HCl. Glc and GlcA reversed the effect of IL-1b
on the expression of AGG and SOX9, but other substances had no effect.
Conclusion: This study shows that glucosamine derivatives can alter anabolic and catabolic processes in HACs
induced by IL-1b. GlcN-S and GluN-HCl decreased induced MMP-3 and -13 expressions, while Glc and GlcA
increased reduced-AGG and SOX9 expression. The chondroprotective study using porcine cartilage explant showed
that GlcN-S had the strongest effect.
Background
Osteoarthritis (OA) is the most common form of arthri-
tis, and is a public health problem throughout the
world. OA is characterized by cartilage deterioration, as
evidenced by quantitative and qualitative modification of
proteoglycans (PGs) and collagen. An imbalance
between the biosynthesis and the degradation of matrix
components leads to a progressive destruction of the tis-
sue, resulting in extensive articular damage [1].
Glucosamine (GlcN) is becoming increasingly popular
as an alternative treatment for OA. GlcN is an
aminosaccharide, acting as a preferred substrate for the
biosynthesis of glycosaminoglycan chains and subse-
quently, for the production of aggrecan and other pro-
teoglycans found in cartilage [2]. There is evidence that
GlcN is equally effective or even better in decreasing
pain in patients with knee OA, as compared to low dose
Non-Steroidal Anti-Inflammatory Drug (NSAID) use
[3,4]. Several clinical studies have indicated that crystal-
line GlcN-S is effective in controlling OA symptoms
and disease progression [5-7]. In addition, the study of
GlcN levels in plasma and synovial fluid suggests that
GlcN is bioactive both systemically and at the site of
action (joint) after oral administration of crystalline
GlcN-S [8]. Although the treatment of OA with GlcN is
quite popular, the exact mechanism of its effects on
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level, remains unknown. There are many reports demon-
strating the effect of GlcN and suggesting that GlcN
reverses the decrease in proteoglycan synthesis and in
UDP-glucuronosyl-transferase I mRNA expression
induced by IL-1b [9]. Moreover, addition of GlcN to rat
chondrocytes treated with IL-1b decreased the activation
of the nuclear factor B, but not the activator protein-1;
GlcN can also increase the expression of mRNA encod-
ing the type II IL-1b receptor (a decoy receptor) [10]. In
human osteoarthritic chondrocytes, it was found that
GlcN-S inhibits the synthesis of proinflammatory media-
tors stimulated by IL-1b through a NFB-dependent
mechanism [11]. Furthermore, the study of anabolic and
catabolic gene expression in human osteoarthritic
explants revealed that GlcN-HCl and GlcN-S downregu-
lated both anabolic and catabolic gene expression [12].
Thus, the therapeutic effects of GlcN may be due to anti-
catabolic activities, rather than due to anabolic activities.
GlcN used for OA treatment is mostly GlcN deriva-
tives, such as GlcN-HCl and Glc-S. There are some
reports that compare the effects of these derivatives. It
was found that GlcN-S is a stronger inhibitor of gene
expression than GlcN-HCl [13]. However, there has to
date been no comparison of the chondroprotective effects
of GlcN derivatives. In this study, we compared the chon-
droprotective effects of GlcN-HCl, GlcN-S, Glc and GlcA
in porcine cartilage explants and human articular chon-
drocytes (HAC) that had been induced by IL-1b.S i n c e
the metabolic imbalance in OA includes both an increase
in cartilage degradation and insufficient reparative or
anabolic response [14], the effects of these glucose deri-
vatives, on both catabolic and anabolic gene expression,
were studied and compared in HAC treated with IL-1b.
Methods
Chemicals
The following chemicals were purchased from Sigma-
Aldrich (USA): D-(+)-Glucose, D-(+)-Glucuronic acid g-
lactone, and D-(+)-Glucosamine hydrochloride. GlcN-S
was obtained from Rottapharm and IL-1b was pur-
chased from R&D (R&D system, USA).
Preparation and treatment of cartilage explants
The cartilage degradation model was performed using
porcine cartilage explant induced inflammation using
IL-1b as described previously [15-17]. Briefly, the meta-
carpophalangeal joints were dissected for articular carti-
lage from 20-24 week-old pigs. These were then
incubated in serum-free Dulbecco’s modified Eagle’s
medium (DMEM) containing 200 units/ml of penicillin
and 200 ug/ml of streptomycin with 5% CO2 and at
37°C. The explants were kept for 24 hours. Recombinant
human interleukin-1b (25 ng/ml) was used to induce
cartilage degradation. The explants were subsequently
co-treated with IL-1b and various concentrations of Glc,
GlcN-S, GlcA and GlcN-HCl (20, 40, 80 mM). The
media were collected on the third day of the treatment
and stored at -20°C for further analysis. It should be
noted that all experiments were performed in triplicate
using tissue from one animal donor.
HAC culture and treatment
Primary chondrocytes were isolated from the non-inflam-
matory human cartilage that was collected after arthro-
scopic diagnosis of flat-pad syndrome patients at the
Maharaj Nakorn Chiang Mai Hospital. Fully informed
written consent was obtained from each patient and the
study was approved by the Research Ethics Committee 3,
Faculty of Medicine, Chiang Mai University (ethics
approval code is 070CT111016). The cartilage was
digested with trypsin at 4°C for 12 hours, and with col-
lagenase (Sigma-Aldrich®, type IA) at 37°C for 3 hours.
Then, the cells were washed with phosphate-buffered sal-
ine (PBS) and grown at high density in a monolayer cul-
ture comprising 10% fetal calf serum (FCS) DMEM. After
the fourth cycle, the human chondrocytes were main-
tained in serum-free DMEM for 24 hours, prior to 24
hours of co-treatment with 10 ng/ml IL-1b and various
concentrations (5, 10, 20 mM) of Glc, GlcN-S, GlcA and
GlcN-HCl. Moreover, the expressions of interested genes
(MMP-3, MMP-13, AGG and SOX9) were also investi-
gated for the comparison between fresh primary isolated
chondrocyte (P0) and its fourth passages.
Cytotoxic study using the MTT assay
HAC (1 × 10
4 cells) were plated in triplicate in 96-well-
plates and incubated overnight. Cells were treated with
different concentrations (5, 10, 20 mM) of Glc, GlcN-S,
GlcA and GlcN-HCl for 24 hours. After incubation, cul-
ture media were discarded, replaced with new culture
media which contained 10% of 5 mg/ml MTT (3,[4,4-
dimethy thiazol-2-yl]-2,5-diphenyl-tetrazolium bromide),
discarded again, and followed by adding 0.2 ml of
dimethyl sulfoxide (DMSO) to each well to solubilize
the formed formazane crystals. The absorbance was
measured at 540 nm using a microplate reader.
Percent of cell survival was calculated as follows:
% survival
Absorbance of test
Absorbance of control
=× 100
Measurement of s-GAG concentration
The concentrations of s-GAG in the conditional media
were measured using dimethylmethylene blue (DMMB)
[18] and a standard of shark cartilage chondroitin sulfate
C (Sigma-Aldrich®, USA). The DMMB solution was used
to dilute the sample, the standards and the appropriate
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was measured at 525 nm using a microplate reader
spectrophotometer. The levels of the ECM biomolecules
released from the cartilage due to induction by IL-1b
were calculated as:
%/           change medium from D medium from D medium from = () − () ⎡ ⎣ ⎤ ⎦ 30    D0 100 () {} ×
where D0 and D3 are media collected on the start day
and the third day, respectively.
Detection of uronic acid
The concentrations of remaining glucuronic acid (GlcUA)
in the explants were measured by a colorimetric assay
using m-hydroxydiphenyl as a reagent [19]. Explants were
digested by papain prior to measurement. The percentage
of remaining uronic acid was calculated as:
Percentage of remaining UA content UA of control UA %{ [ ( ) ( () =−              
  
of treatment
UA of control
)] /
} () ×100
Measurement of HA concentration
HA concentrations were measured using the competitive
inhibition-based enzyme-linked immunosorbent assay
(ELISA) method using the commercialized AWHA Test
kit [20] (Allswell Singapore Pte., Singapore) according to
the manufacturer’s instructions.
Gelatin zymography
Pro-MMP-2 in the conditioned medium was detected by
gelatin zymography as previously described [21]. The
samples were subjected to sodium dodecyl sulfate polya-
crylamide gel electrophoresis (SDS-PAGE) using 10%
acrylamide gel containing 0.1 mg/ml of gelatin (Sigma-
Aldrich®, USA) at 4°C under non-reducing conditions.
After electrophoresis, SDS in the gel was removed by
rinsing with 2.5% Triton-X 100 pH 7.5. The gel was
then incubated at 37°C in the buffer (50 mM Tris-HCl,
5m MC a C l 2,1μMZ n C l 2, 0.02% NaN3) for 18 hours
and then stained with 0.1% Coomassie brilliant blue
R250 (Bio-Rad Laboratories, Hercules, CA) in 50%
methanol/10% acetic acid, and destained with 10% acetic
acid/50% methanol. Finally, a Scion image densitometer
was utilized to analyse the gelatinolytic activity.
Gene expression analysis
RNA was extracted from the monolayer cells using an
Aurum total RNA purification kit (Bio-Rad Laboratories,
Hercules, CA, USA). Using the RevertAid™ First Stand
cDNA synthesis kit (MBI Fermentas, Germany), the net
sum RNA (500 ng) of each sample was reverse
transcribed into complementary DNA (cDNA). Primer
and probe sets were designed using Primer Express 2.0
software (Applied Biosystems, Foster City, CA, USA) and
nucleotide sequences are: AGG; 5′ ACTTCCGCT-
GGTCAGATGGA3′ 3′ CAACACTGCCAACGTCCA-
GAT5′,S O X 9 ;5 ′ ACACACAGCTCACTCGACCTTG 3′,
3′ GGAATTCTGGTTGGTCCTCTCTT 5′, MMP-3; 5′
TTTTGGCCATCTCTTCCTTCA 3′,3 ′ TGTGGATG-
CCTCTTGGG TATC5′, MMP-13; 5′ TCCTCTTCT-
TGAGCTGGACTCATT 3′,3 ′ CGCTCTG CAAACT
GGAGGTC 5′,G A P D H ;5 ′ GAAGGTGAAGGTCG-
GAGTC3′,3 ′ GAAGATGGTGATGGGATTTC 5′.T h e
amplified products were separated by electrophoresis on
2% (w/v) agarose gels, stained with ethidium bromide
and then imaged using a Bio-Rad Gel-Doc fluorescent
image analyzer. To allow semi-quantitative comparisons
of mRNA levels, the integrated densities were calculated
by the Scion Image analysis software and divided by
levels of the house-keeping gene GAPDH (glyceralde-
hydes-3-phosphate dehydrogenase) as previously
described [22,23].
Statistical analysis
All data were shown as mean ± SD and the statistical
analysis was performed using t-tests. P-values less than
0.05 were considered significant.
Results
Chondroprotective effects of Glc, GlcN-S, GlcA and GlcN-
HCl in porcine cartilage explants
Porcine cartilage explants were induced to degrade by
using 25 ng/ml IL-1b and the chondroprotective effects
of all four chemicals were studied by co-treating the
explants with IL-1b and each chemical (20, 40, 80 mM)
for 3 days. Conditioned media were collected and ana-
lyzed. Many molecules were used to be the indicators.
Interleukin-1 beta induces the degradation of extracellu-
lar matrix (ECM) molecules in cartilage discs, and
degraded ECM molecules will be released into the
media while undegraded molecules will remain in the
cartilage tissue.
The release of HA and s-GAG, which are ECM mole-
cules, from cartilage tissue into media were analyzed by
ELISA and dye-binding assays, respectively. Gelatin
zymography was used to measure MMP-2 activity. The
remnant ECM molecules were measured by digestion of
conditioned cartilage with papain, followed by measur-
ing the remaining uronic acid.
IL-1b induced the release of HA and s-GAG from car-
tilage into media (Figure 1A, B). GlcN-S, GlcN-HCl and
GlcA decreased HA release. Among these three chemi-
cals, GlcN-S exhibited the highest inhibitory effect.
However, HA released to the media was not reduced
by Glc (Figure 1A). For s-GAG releases, GlcN-S and
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Glc and GlcA did not. GlcN-S also had the highest
effect on s-GAG. Moreover, IL-1b induced the activity
of MMP-2 (Figure 2). This induced activity was
decreased by GlcA, GlcN-HCl and GlcN-S, but not by
Glc. Similarly to HA and s-GAG, GlcN-S possessed the
highest inhibitory effect.
For the remaining uronic acid in cartilage discs, when
the cartilage discs were treated with IL-1b,t h er e m a i n -
ing uronic acid content was lower than that of the con-
trol group (Figure 1C). All four chemicals did not
significantly reverse this effect of IL-1b, but GlcN-S and
GlcN-HCl tended to inhibit uronic acid loss from carti-
lage at the highest dosage (80 mM). Altogether, these
results suggest that GlcN-S had the highest chondropro-
tective effect among all four chemicals used in our por-
cine cartilage explant model. We continued by analyzing
the chondroprotective effects of all four chemicals in
human chondrocytes.
Cytotoxic effects of Glc, GlcN-S, GlcA and GlcN-HCl in HAC
The cytotoxic effects of 5, 10 and 20 mM of all four
chemicals were initially studied in the HAC model. As
s h o w ni nF i g u r e3 ,n o n eo ft h et h r e ec o n c e n t r a t i o n so f
the four chemicals had cytotoxic effects on HAC. Thus,
these three concentrations could be used for studying
the chondroprotective effects of the chemicals in subse-
quent experiments.
Effects of Glc, GlcN-S, GlcA and GlcN-HCl on HA release
and MMP-2 activity in IL-1b-treated-HAC
HACs were co-treated with 10 ng/ml IL-1b and 5, 10
and 20 mM of each chemical for 24 hours. The condi-
tioned media were collected and analyzed for HA and
MMP-2 activity.
IL-1b was able to induce the release of HA and MMP-2
activity into the media (Figure 4). The induced released
HA was inhibited by GlcN-S, Glc and GlcN-HCl but was
not inhibited by GlcA. GlcN-S showed the highest
Figure 1 The effects of Glc, GlcN-S, GlcA and GlcN-HCl: release of s-GAG, HA from porcine cartilage tissues to the media, the uronic
acid remaining in the cartilage tissue. Porcine cartilage explants were cultured with IL-1b (25 ng/ml) in absence and presence of each
chemical (at varying concentrations of 20, 40, 80 mM) for 3 days. In the media, the s-GAG release was measured by using a dye-binding assay,
and HA release was measured by ELISA. Cartilage discs were digested with papain and then the uronic acid content was measured. *, **
Denotes: a value that is significantly different (p < 0.05 and p < 0.01, respectively) from the IL-1b control.
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Page 4 of 12Figure 2 Effects of Glc, GlcN-S, GlcA and GlcN-HCl on the production of MMP-2. Porcine cartilage explants were cultured with IL-1b (25
ng/ml) in the absence and presence of each chemical (at varying concentrations of 20, 40, 80 mM) for 3 days. Media were collected and were
then analyzed by gelatin zymography as described in the text. Three experiments were carried out independently and they were reproducible. *,
** Denotes a value that is significantly different (p < 0.05 and p < 0.01, respectively) from the IL-1b control.
Figure 3 The cytotoxic effects of Glc, GlcN-S, GlcA and GlcN-HCl. The cytotoxic effect of all reagents at concentrations 5, 10 and 20 mM in
human articular chondrocytes were studied by the MTT assay.
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Page 5 of 12Figure 4 Effects of Glc, GlcN-S, GlcA and GlcN-HCl on the release of HA (A), s-GAG (B) and MMP-2 (C) from chondrocytes. Chondrocytes
were co-treated with 10 ng/ml IL-1b and various concentrations of each chemical (5, 10, 20 mM) for 24 hours. The conditioned media were
analyzed for HA, s-GAG and MMP-2 activity as described in the Experimental section. *,** Denotes a value that is significantly different (p<0.05
and p<0.01, respectively) from the IL-1b control.
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4A). Glc and GlcA did not decrease induced MMP-2
activity, whereas both GlcN-S and GlcN-HCl did so.
Among the four chemicals studied, GlcN-S had the high-
est inhibitory effect (Figure 4B). In the human chondro-
cyte model, GlcN-S also had the highest
chondroprotective effect.
Effects of Glc, GlcN-S, GlcA and GlcN-HCl on catabolic
gene expression in HAC
To study gene expression, HACs were co-treated with
10 ng/ml IL-1b and 5, 10 and 20 mM of each chemical
for 24 hours. Cells were harvested and then extracted
for mRNA, which was used to synthesize cDNA. The
R T - P C Rw a sp e r f o r m e du s i n gt h ep r i m e r sa sd e s c r i b e d
in Methods.
It has been well documented that the expression levels
of many genes change in cultured chondrocytes as com-
pared to that in intact cartilage and, moreover, between
the cultured passages [24-27]. To avoid the variations of
the expression levels between passages, the genes show-
ing negligible change between passage cultures were
chosen for further investigation. There was a report
found that the expression of MMP-3, MMP-13, aggre-
can core protein (AGG) and SOX-9 (a transcriptional
factor for type II collagen) were not significantly chan-
ged between fresh isolated chondrocytes (passage 2) and
used passage (passage 4) [28]. In agreement with pre-
vious studies, we found that MMP-3, MMP-13, AGG
and SOX9 mRNA expressions in P4 cultured chondro-
cytes were not significantly different with fresh isolated
chondrocytes (Figure 5). Due to there was no variation
of these genes between P0 and P4 cultured chondro-
cytes, thus MMP-3, MMP-13, AGG and SOX9 gene
expressions were chosen for further investigation.
Regarding the expression of catabolic genes, we stu-
died MMP-3 and MMP-13. Both MMP-3 and -13 gene
expressions were induced by IL-1b (Figure 6). The
induced MMP-3 expression was inhibited by GlcN-HCl
and GlcN-S, while GlcN-HCl showing the highest inhi-
bitory effect. Glc and GlcA had no inhibitory effect on
expression of either gene. On the contrary, Glc and
GlcA seemed to further induce MMP-3 expression. For
MMP-13, GlcN-HCl and GlcN-S could inhibit the
induction of MMP-13 by IL-1b, and GlcN-S showed the
highest inhibitory effect. Glc had no effect on induced
MMP-13 expression, but GlcA increased MMP-13
expression.
Effects of Glc, GlcN-S, GlcA and GlcN-HCl on anabolic
gene expressions in HAC
Regarding the effects of the tested compounds on ana-
bolic genes, we analyzed the expression of AGG and
SOX9. There was no significant difference in expression
of either AGG or SOX9 genes when treated with IL-1b
(Figure 7). Glucose and GlcA induced AGG gene
expression, while GlcN-HCl and GlcN-S showed
reduced effects. The GlcN-HCl group had the highest
Figure 5 The mRNA expression of MMP-3, MMP-13, AGG and SOX9 in fresh isolated chondrocytes (P0) and in the fourth cultured
passage chondrocytes (P4). Passage 0 and P4 confluent human chondrocytes in 25-cm
3 flasks were cultured in serum free-DMEM for 24
hours. Cells were harvested and gene expression was analyzed. MMP, matrix metalloproteinase, AGG, aggrecan; SOX9, SRY-type HMG box.
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with Glc or GlcN-S, but was increased by GlcA and was
decreased by GlcN-HCl.
Discussion
Osteoarthritis (OA) is the most common form of arthri-
tis, affecting millions of people worldwide [29]. It
remains the major cause of disability in the elderly,
affecting about 60% of men and 70% of women above
the age of 65. As regards therapeutic strategies for OA,
there are a large number of active research and drug
discovery programs aimed to identify structure-modify-
ing ways to inhibit joint destruction in OA, and existing
drug therapies to reduce symptoms. None of these
approaches, however, has significant efficacy as a disease
modifying anti-OA drug [30]. Until recently, COX-2
inhibitors were widely used to provide symptomatic
relief, but the increased risk of heart attacks and strokes
associated with these drugs led to the recall of some
products from the market and warnings concerning
their use [31,32]. As alternatives to non-steroidal anti-
inflammatory drugs (NSAIDs) and COX-2 inhibitors,
other symptom-modifying drugs currently in clinical
trials for OA include nitric oxide-releasing analgesics,
bradykinin B2 receptor antagonists and capsaisin analo-
gues [33]. Other treatments for OA could include intra-
articular injection with long-acting corticosteroids or
hyaluronan, which would also provide symptomatic
Figure 6 Effect of Glc, GlcN-S, GlcA and GlcN-HCl on the mRNA expression of proteinases [MMP-3 (A), -13 (B)]. Confluent human
chondrocytes in 25-cm
3 flasks were cultured with IL-1b (10 ng/ml) in the presence and absence of each chemical for 24 hours. Cells were
harvested and gene expression was analyzed. MMP, matrix metalloproteinase. *, ** Denotes a value that is significantly different (p < 0.05 and p
< 0.01, respectively) from the IL-1b control.
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treatment. Glucosamine (GlcN) is becoming increasingly
popular as an alternative treatment for OA. There is evi-
dence that GlcN is equally eff e c t i v eo re v e nb e t t e ri n
decreasing pain in patients with knee OA, as compare
to low dose NSAID use [3,4]. Furthermore, there are
several reports showing that there was less joint space
narrowing in people with knee OA who took GlcN
compared to placebo, over a period of 3 years [34,35].
This suggests that that GlcN can delay the progression
of knee OA. In the last several decades, there has been
an increasing number of patients who have started using
GlcN, with or without direction from a physician.
Although the effectiveness of GlcN has been debated in
a recent article, there are clinical studies suggesting that
GlcN probably has structure modifying effects in
patients with knee OA [34,35]. The underlying effects of
GlcN on cartilage that are responsible for these clinical
outcomes are still unclear. It has been proposed that
addition of GlcN to chondrocyte cell cultures leads to
more GAG production, since GlcN is the basic building
block of GAG molecules. Some studies have supported
this hypothesis [36-40]. However, there are studies that
observed negative effects on GAG production after
GlcN addition [10,41-45]. Apart from influencing matrix
synthesis, several studies have shown that GlcN is also
Figure 7 Effects of Glc, GlcN-S, GlcA and GlcN-HCl on the mRNA expression of cartilage genes [AGG (A), SOX9 (B)]. Confluent human
chondrocytes in 25-cm
3 flasks were cultured with IL-1b (10 ng/ml) in the presence and absence of each chemical for 24 hours. Cells were
harvested and gene expression was analyzed. AGG, aggrecan; SOX9, SRY-type HMG box. *, ** Denotes a value that is significantly different (p <
0.05 and p < 0.01, respectively) from the IL-1b control.
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[9,46-49]. These conflicting results can have various
causes.
It is unclear whether or not GlcN-S, Glc-HCl and N-
acetyl-glucosamine (GlcN-Ac) have similar effects on
cartilage. Differences in the results can also be
explained by the varieties of culture models used (e.g.,
monolayer or pellet culture) and the variations in cul-
ture duration.
No previous studies have examined the metabolism of
GlcN in humans. However, there is one published inves-
tigation of synovial and plasma GlcN concentrations in
OA patients following oral administration of crystalline
GlcN-S. That study reported that GlcN is bioavailable
both systemically and at the site of action (the joint) [8].
However, it is still unclear whether the administrated
GlcN will be metabolized to Glc in humans, and
whether metabolized Glc will have effects similar to
those of GlcN. Thus, in this experiment, we studied and
compared the effects of Glc, GlcA, GlcN-S and GlcN-
HCl in two models using IL-1b to induce inflammtion:
first in a porcine cartilage explant model, and second, in
a human articular chondrocyte (HAC) culture model. In
the porcine cartilage explant model, GlcN-S showed the
highest chondroprotective effects (inhibited IL-1b’s
effect on HA and s-GAG degradation) followed by
GlcN-HCl, while Glc and GlcA did not show these
effects. In the HAC model, GlcN-S had the highest
effect, shown by inhibition of IL-1b induced HA release
and MMP-2 activity, followed by GclN-HCl and GlcA,
but Glc had no effect. Thus in administration of glucose
derivatives, if these reagents were metabolized to Glc,
the metabolized compound might not have a chondro-
protective effect.
There are also reports showing that GlcN decreases
expression of both anabolic and catabolic genes in
human OA cartilage explants [12]. We expected that
GlcN-S would show the highest inhibitory effect on IL-
1b, because it had the highest effect in porcine cartilage
explants. But our results showed that only MMP-13
gene expression could be reduced by GlcN-S. For the
other catabolic gene, MMP-3 was mostly inhibited by
GlcN-HCl, inversely with Glc, and GlcA further induced
both MMP-3 and -13 expression in HAC treated with
IL-1b.I na n a b o l i cg e n ee x p r e s s i o n ,b o t hA G Ga n d
SOX9 gene expression were not significantly changed by
IL-1b. AGG expression was induced by Glc and GlcA,
but was reduced by GlcN-S and GlcN-HCl. SOX9
expression was increased by GlcA and decreased by
GlcN-HCl. Altogether, it seemed that Glc and GlcA
could induce both catabolic and anabolic gene
expression while GlcN-S and GlcN-HCl reduced the
expression of the catabolic genes.
Conclusion
Our results illustrate two key points. Firstly, from the
chondroprotective study, GlcN-S had the most signifi-
cant effect. However, at the mechanistic level of gene
expression, GlcN-S had the strongest effect only on
MMP-13 expression. Secondly, GlcN-HCl and GlcN-S
showed significant effects on catabolic gene expression
but not on anabolic genes, whereas Glc and GlcA had
significant effects on anabolic genes but not on catabolic
genes. However, if we consider chondroprotective
effects, GlcN-HCl and GlcN-S were more effective than
Glc and GlcA. Here, we used normal HAC and induced
inflammation by IL-1b to mimic the onset of OA. These
results thus demonstrate the importance of inhibition of
catabolic genes in the onset of the disease.
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